Vaccination with vif-deleted feline immunodeficiency virus provirus, GM-CSF, and TNF-α plasmids preserves global CD4 T lymphocyte function after challenge with FIV

Vaccine

Volumn 27, Issue 28, 2009, Pages 3754-3765

  Maksaereekul, Saipiroon ^a   Dubie, Robert A ^a   Shen, Xiaoying ^a   Kieu, Hung ^a   Dean, Gregg A ^b   Sparger, Ellen E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Cytokine adjuvants; DNA vaccine; FIV

Indexed keywords

DNA VACCINE; INTERLEUKIN 15; INTERLEUKIN 2; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VIF PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CAT; CD4+ T LYMPHOCYTE; CELL STRAIN COS7; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG EFFICACY; FELINE IMMUNODEFICIENCY VIRUS; FLOW CYTOMETRY; GENE DELETION; IMMUNOGENICITY; INOCULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; VIRUS LOAD; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CATS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; GENE DELETION; GENE PRODUCTS, VIF; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNODEFICIENCY VIRUS, FELINE; PROVIRUSES; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, DNA; VIRAL LOAD; VIRAL VACCINES;

EID: 67349237505     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.081     Document Type: Article

References (71)

1. Dunham S.P. Lessons from cat: development of vaccines against lentiviruses. Vet Immunol Immunopathol 112 1-2 (2006) 67-77
2. Lecollinet S., and Richardson J. Vaccination against the feline immunodeficiency virus: the road not taken. Comp Immunol Microbiol Infect Dis 31 2-3 (2008) 167-190
3. Uhl E.W., Martin M., Coleman J.K., and Yamamoto J.K. Advances in FIV vaccine technology. Vet Immunol Immunopathol 15 1-2 (2008) 65-80
4. Boretti F.S., Leutenegger C.M., Mislin C.N., Hofmann-Lehmann R., Koenig S., Schroff M., et al. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression. AIDS 14 12 (2000) 1749-1757
5. Dunham S.P., Flynn J.N., Rigby M.A., Macdonald J., Bruce J., Cannon C., et al. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine 20 11-12 (2002) 1483-1496
6. Hosie M.J., Flynn J.N., Rigby M.A., Cannon C., Dunsford T., Mackay N.A., et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol 72 9 (1998) 7310-7319
7. Leutenegger C.M., Boretti F.S., Mislin C.N., Flynn J.N., Schroff M., Habel A., et al. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif. J Virol 74 22 (2000) 10447-10457
8. Barouch D.H., Letvin N.L., and Seder R.A. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev 202 (2004) 266-274
9. Berinstein N.L. Enhancing cancer vaccines with immunomodulators. Vaccine Suppl. 2 (2007) B72-B88
10. Hokey D.A., and Weiner D.B. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 28 3 (2006) 267-279
11. Morrow M.P., and Weiner D.B. Cytokines as adjuvants for improving anti-HIV responses. AIDS 22 3 (2008) 333-338
12. Xu R., Megati S., Roopchand V., Luckay A., Masood A., Garcia-Hand D., et al. Comparative ability of various plasmid-based cytokines and chemokines to adjuvant the activity of HIV plasmid DNA vaccines. Vaccine 6 37 (2008) 4819-4829
13. Flynn J.N., Hosie M.J., Rigby M.A., Mackay N., Cannon C.A., Dunsford T., et al. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination. Vaccine 18 11-12 (2000) 1118-1132
14. Lockridge K., Himathongkham S., Sawai E.T., Chien M., and Sparger E.E. The feline immunodeficiency virus vif gene is required for productive infection of feline peripheral blood mononuclear cells and monocyte-derived macrophages. Virology 261 1 (1999) 25-30
15. Lockridge K., Chien M., Luciw P.A., and Sparger E.E. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 273 1 (2000) 67-79
16. Gupta S., Leutenegger C.M., Dean G.A., Steckbeck J.D., Cole K.S., and Sparger E.E. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon. J Virol 81 2 (2007) 465-473
17. Ahlers J.D., Belyakov I.M., and Berzofsky J.A. Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. Curr Mol Med 3 3 (2003) 285-301
18. Fleetwood A.J., Cook A.D., and Hamilton J.A. Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 25 5 (2005) 405-428
19. Haddad D., Ramprakash J., Sedegah M., Charoenvit Y., Baumgartner R., Kumar S., et al. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 165 7 (2000) 3772-3781
20. Kim J.J., Yang J., Lee D.J., Wilson D.M., Nottingham L.K., Dentchev T., et al. Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. Hum Gene Ther 11 2 (2000) 305-321
21. Lee S.W., Cho J.H., and Sung Y.C. Optimal induction of hepatitis C virus envelope-specific immunity by bicistronic plasmid DNA inoculation with granulocyte-macrophage colony-stimulating factor gene. J Virol 72 10 (1998) 8430-8436
22. Barouch D.H., Santra S., Tenner-Racz K., Racz P., Kuroda M.J., Schmitz J.E., et al. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168 2 (2002) 562-568
23. Lai L., Vödrös D., Kozlowski P., Montefiori D., Wilson R., Akerstrom V., et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. Virology 369 1 (2007) 153-167
24. Robinson H.L., Montefiori D.C., Villinger F., Robinson J.E., Sharma S., Wyatt L.S., et al. Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. Virology 352 2 (2006) 285-294
25. Aggarwal B.B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3 9 (2003) 745-756
26. Fiers W. Tumor necrosis factor: characterization at the molecular, cellular and in vivo level. FEBS Lett 285 2 (1991) 199-212
27. Shimizu Y., Miyazaki Y., Ibuki K., Suzuki H., Kaneyasu K., Goto Y., et al. Induction of immune response in macaque monkeys infected with simian-human immunodeficiency virus having the TNF-α gene at an early stage of infection. Virology 343 2 (2005) 151-161
28. Su B., Wang J., Wang X., Jin H., Zhao G., Ding Z., et al. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 26 40 (2008) 5111-5122
29. Ahlers J.D., Belyakov I.M., Matsui S., and Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int Immunol 13 7 (2001) 897-908
30. Surh C.D., Boyman O., Purton J.F., and Sprent J. Homeostasis of memory T cells. Immunol Rev 211 (2006) 154-163
31. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 6 8 (2006) 595-601
32. Waldmann T.A., Dubois S., and Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14 2 (2001) 105-110
33. Becker T.C., Wherry E.J., Boone D., Murali-Krishna K., Antia R., Ma A., et al. Interleukin 15 is required for proliferative renewal of virus-specific memory CD8 T cells. J Exp Med 195 12 (2002) 1541-1542
34. Oh S., Perera L.P., Terabe M., Ni L., Waldmann T.A., and Berzofsky J.A. IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis. Proc Natl Acad Sci USA 105 13 (2008) 5201-5206
35. Picker L.J., Reed-Inderbitzin E.F., Hagen S.I., Edgar J.B., Hansen S.G., Legasse A., et al. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest 116 6 (2006) 1514-1524
36. Saikh K.U., Kissner T.L., Nystrom S., Ruthel G., and Ulrich R.G. Interleukin-15 increases vaccine efficacy through a mechanism linked to dendritic cell maturation and enhanced antibody titers. Clin Vaccine Immunol 15 1 (2008) 131-137
37. Gemeniano M.C., Sawai E.T., Leutenegger C.M., and Sparger E.E. Feline immunodeficiency virus orf-A is required for virus particle formation and virus infectivity. J Virol 77 16 (2003) 8819-8830
38. Dean G.A., Barger A., and Lavoy A. Cloning and expression of feline interleukin 15. Cytokine 29 2 (2005) 77-83
39. Rimstad E., Reubel G.H., Dean G.A., Higgins J., and Pedersen N.C. Cloning, expression and characterization of biologically active feline tumour necrosis factor-alpha. Vet Immunol Immunopathol 45 3-4 (1995) 297-310
40. Sambrook J., Fritsch E.F., and Maniatis T. Molecular cloning: a laboratory manual (1989), Cold Spring Harbor Laboratory Press
41. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoientin. J Cell Physiol 140 2 (1989) 323-334
42. George J.W., Pedersen N.C., and Higgins J. The effect of age on the course of experimental feline immunodeficiency virus infection. AIDS Res Hum Retroviruses 9 9 (1993) 897-905
43. Pedersen N.C., Leutenegger C.M., Woo J.C., and Higgins J. Virulence differences between two fields isolates in feline immunodeficiency virus (FIV-APetaluma and FIV-CpGammar) in young adult specific pathogen free cats. Vet Immunol Immunopathol 79 1-2 (2001) 53-67
44. Sparger E.E., Beebe A.M., Dua N., Elder J., Himathongkam S., Torten M., et al. Infection of cats with molecularly cloned and biological isolates of the feline immunodeficiency virus. Virology 205 2 (1994) 546-553
45. Ito M., Watanabe M., Kamiya H., and Sakurai M. Changes in intracellular cytokine levels in lymphocytes induced by measles virus. Clin Immunol Immunopathol 83 3 (1997) 281-286
46. Petersen C.M., Christensen E.I., Andresen B.S., and Moller B.K. Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T lymphocytes and U-937 cells. Exp Cell Res 201 1 (1992) 160-173
47. Hanke T., McMichael A.J., Samuel R.V., Powell L.A., McLoughlin L., Crome S.J., et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA-and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21 1-2 (2002) 108-114
48. Parker S.E., Borellini F., Wenk M.L., Hobart P., Hoffman S.L., Hedstrom R., et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. Hum Gene Ther 10 5 (1999) 741-758
49. Tuomela M., Malm M., Wallen M., Stanescu I., Krohn K., and Peterson P. Biodistribution and general safety of a naked DNA plasmid, GTU-MultiHIV, in a rat, using a quantitative PCR method. Vaccine 23 7 (2005) 890-896
50. Morita Y., Yamamura M., Kawashima M., Harada S., Tsuji K., Shibuya K., et al. Flow cytometric single-cell analysis of cytokine production by CD4 T cells in synovial tissue and peripheral blood from patients with rhematoid arthritis. Arthritis Rheu 41 9 (1998) 1669-1676
51. Openshaw P., Murphy E.E., Hosken N.A., Maino V., Davis K., Murphy K., et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 182 5 (1995) 1357-1367
52. Akerele T., Galatowicz G., Bunce C., Calder V., Lynn W.A., and Lightman S. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy. Clin Immunol 121 2 (2006) 191-197
53. Bostik P., Noble E.S., Stephenson S.T., Villinger F., and Ansari A.A. CD4+ T cells from simian immunodeficiency virus disease-resistant sooty mangabeys produce more IL-2 than cells from disease-susceptible species: involvement of p300 and CREB at the proximal IL-2 promoter in IL-2 up-regulation. J Immunol 178 12 (2007) 7720-7729
54. Clerici M., Hakim F.T., Venzon D.J., Blatt S., Hendrix C.W., Wynn T.A., et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic, human immunodeficiency virus-seropositive individuals. J Clin Invest 91 3 (1993) 759-765
55. McKay P.F., Barouch D.H., Schmitz J.E., Veazey R.S., Gorgone D.A., Lifton M.A., et al. Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol 77 8 (2003) 4695-4702
56. Sirskyj D., Thèze J., Kumar A., and Kryworuchko M. Disruption of the gamma c cytokine network in T cells during HIV infection. Cytokine 43 1 (2008) 1-14
57. Sun Y., Schmitz J.E., Acierno P.M., Santra S., Subbramanian R.A., Barouch D.H., et al. Dysfunction of simian immunodeficiency virus/simian human immunodeficiency virus-induced IL-2 expression by central memory CD4+ T lymphocytes. J Immunol 174 8 (2005) 4753-4758
58. De Groot-Mijnes J.D., Van der Most R.G., Van Dun J.M., Te Lintelo E.G., Schuurman N.M., Egberink H.F., et al. Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the cat. J Immunol Methods 285 1 (2004) 45-54
59. Desrosiers R.C., Lifson J.D., Gibbs J.S., Czajak S.C., Howe A.Y., Arthur L.O., et al. Identification of highly attenuated mutants of simian immunodeficiency virus. J Virol 72 7 (1998) 1431-1437
60. Harmache A., Russo P., Guiguen F., Vitu C., Vignoni M., Bouyac M., et al. Requirement of caprine arthritis encephalitis virus vif gene for in vivo replication. Virology 224 1 (1996) 246-255
61. Shen X., Leutenegger C.M., Cole K.S., Pedersen N.C., and Sparger E.E. A feline immunodeficiency virus vif-deletion mutant remains attenuated upon infection of newborn kittens. J Gen Virol 88 Pt10 (2007) 2793-2799
62. Armitage R.J., Macduff B.M., Eisenman J., Paxton R., and Grabstein K.H. IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154 2 (1995) 483-490
63. Kacani L., Sprinzl G.M., Erdei A., and Dierich M.P. Interleukin-15 enhances HIV-1 driven polyclonal B-cell response in vitro. Exp Clin Immunogenet 16 3 (1999) 162-172
64. Park C., Yoon S., Armitage R.J., and Choi Y.S. Follicular dendritic cells produce IL-15 that enhances germinal center B cell proliferation in membrane-bound form. J Immunol 173 11 (2004) 6676-6683
65. Sprent J., Cho J.H., Boyman O., and Surh C.D. T cell homeostasis. Immunol Cell Biol 87 1 (2009) 46-49
66. Dunham S.P., Bruce J., Klein D., Flynn J.N., Golder M.C., MacDonald S., et al. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus. Vaccine 24 49-50 (2006) 7095-7108
67. Pistello M., Bonci F., Flynn J., Norman, Mazzetti P., Isola P., et al. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the acccessory ORF-A protein and DNA as protective immunogen. J Virol 80 18 (2006) 8856-8868
68. Terwee J.A., Carlson J.K., Sprague W.S., Sondgeroth K.S., Shropshire S.B., Troyer J.L., et al. Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus. Virology 377 July (1) (2008) 63-70
69. Tanaka M., Hirabayashi Y., Gatanaga H., Aizawa S., Hachiya A., Takahashi Y., et al. Reduction in interleukin-2 producing cells but not Th1 to Th2 shift in moderate and advanced stages of human immunodeficiency virus type-1 infection: direct analysis of intracellular cytokine concentrations in CD4+ CD8- T cells. Scand J Immunol 50 5 (1999) 550-554
70. Dubie R.A., Maksaereekul S., Shacklett B.L., Lemongello D., Cole K.S., Villinger F., et al. Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386 March (1) (2009) 109-121
71. Sparger E.E., Dubie R.A., Shacklett B.L., Cole K.S., Chang W.L., and Luciw P.A. Vaccination of rhesus macaques with a vif-deleted simian immunodeficiency virus proviral DNA vaccine. Virology 374 2 (2008) 261-272